Clinical Trial: CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558434) titled 'CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA' on April 23.

Brief Summary: This study aimed to explore the efficacy and safety of cyclosporine (CsA)

+eltrombopag (EPAG)/hetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Severe Aplastic Anemia (SAA) Transfusion-dependent Non-severe Aplastic Anemia

Intervention: DRUG: Cyclosporine (CsA)

CsA 3-5mg/kg/d, trough concentration 100-200ng/ml

DRUG: thrombopoietin receptor agonist (TPO-RA)

Eltrombopag 50...